This article is more than 5 years old. Information may no longer be current.

Lensar closes financing round of up to $87 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Lensar has raised $27 million in private equity financing and up to $60 million in debt financing to support market expansion of the Lensar laser system for refractive laser-assisted cataract surgery, according to a news release.

Funds will be used to support Lensar’s long-term growth and commercialization efforts in select markets worldwide and help pay for further developments of the Lensar platform, the release said.

PDL BioPharma, a new investor, is providing the debt financing. Aisling Capital, Florida Growth and Florida Opportunity Funds took part in the equity round.

The Lensar system has received clearance from the U.S. Food and Drug Administration to be used during cataract surgery for corneal and arcuate incisions, lens fragmentation, and anterior capsulotomy with or without phacofragmentation.